References
- PfäffleRHormone replacement therapy in children: the use of growth hormone and IGF-IBest Pract Res Clin Endocrinol Metab2015293 339 35226051295
- AllenDBBackeljauwPBidlingmaierMGH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adultsEur J Endocrinol20161742 P1 P926563978
- Albertsson-WiklandKMartenssonASavendahlLMortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristicsJ Clin Endocrinol Metab20161015 2149 215926918292
- CarelJCButlerGSafety of recombinant human growth hormoneEndocr Dev201018 40 5420523016
- AhangariGOstadaliMRRabaniARashidianJSanatiMHZarindastMRGrowth hormone antibodies formation in patients treated with recombinant human growth hormoneInt J Immunopathol Pharmacol2004171 33 3815000864
- RomerTPeterFSaengerPEfficacy and safety of a new ready-to-use recombinant human growth hormone solutionJ Endocrinol Invest2007307 578 58917848841
- RomerTSaengerPPeterFSeven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III studyHorm Res2009726 359 36919844125
- López-SigueroJBorrás PérezMVBalserSKhan-BolukiJLong-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III studyAdv Ther20112810 879 89321948492
- Borrás PérezVLópez-SigueroJPMartínezGA follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trialAdv Ther2015322 148 15625667132
- PfäffleRSchwabKOMargineanODesign of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® in children requiring growth hormone treatmentTher Adv Endocrinol Metab201341 3 1123515245
- PfäffleRKanumakalaSHöybyeCFour-year results from PATRO Children, a multi-centre, non-interventional study of the long-term safety and efficacy of Omnitrope® in children requiring growth hormone treatmentPoster presented at: 55th Annual Meeting of the European Society for Paediatric EndocrinologySeptember 10–12, 2016Paris, France
- SchwarzHPBirkholz-WalerzakDSzaleckiMOne-year data from a long-term phase IV study of recombinant human growth hormone in short children born small for gestational ageBiol Ther201441–2 1 1324676989
- SchwarzHPWalczakMBirkholz-WalerzakDTwo-year data from a long-term phase IV study of recombinant human growth hormone in short children born small for gestational ageAdv Ther2016333 423 43426886776
- Beck-PeccozPMinutoFLeal-CerroAZabranskyMStallaGRationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® for the treatment of adult patients with growth hormone deficiencyTher Adv Endocrinol Metab201233 85 9123148199
- Beck-PeccozPHöybyeCMurrayRLatest results from the PATRO Adults study of Omnitrope® for the treatment of adult patients with growth hormone deficiencyPoster presented: 18th European Congress of EndocrinologyMay 28–31, 2016Munich, Germany
- RashidNSaengerPWuYLSwitching to Omnitrope® from other recombinant human growth hormone therapies: a retrospective study in an integrated healthcare systemBiol Ther201441–2 27 3925096555
- GrimbergAFeudtnerCGordonCMConsequences of brand switches during the course of pediatric growth hormone treatmentEndocr Pract2012183 307 31621940275
- RomerTZabranskyMWalczakMSzaleckiMBalserSEffect of switching recombinant human growth hormone: comparative analysis of phase 3 clinical dataBiol Ther201111 524392295
- FlodmarkCELiljaKWoehlingHJärvholmKSwitching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from SwedenBiol Ther20133 35 4324392303
- RyffJCSchellekensHImmunogenicity of rDNA-derived pharmaceuticalsTrends Pharmacol Sci2002236 254 25612084625
- JelkmannWBiosimilar recombinant human erythropoietins (“epoetins”) and future erythropoiesis-stimulating treatmentsExpert Opin Biol Ther2012125 581 59222471247
- SchellekensHBiosimilar therapeutics – what do we need to consider?NDT Plus20092Suppl 1 i27 i3619461855
- European Medicines Agency (EMA)Genotropin® summary of product characteristics Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Genotropin_7_5/WC500013685.pdfAccessed July 22, 2016